KR101109348B1 - Ｉ.ａ. 탈수초성 염증 질환을 치료하기 위한 ｃｃｒ１ 길항제 - Google Patents

Ｉ.ａ. 탈수초성 염증 질환을 치료하기 위한 ｃｃｒ１ 길항제 Download PDF

Info

Publication number
KR101109348B1
KR101109348B1 KR1020057008518A KR20057008518A KR101109348B1 KR 101109348 B1 KR101109348 B1 KR 101109348B1 KR 1020057008518 A KR1020057008518 A KR 1020057008518A KR 20057008518 A KR20057008518 A KR 20057008518A KR 101109348 B1 KR101109348 B1 KR 101109348B1
Authority
KR
South Korea
Prior art keywords
disease
pharmaceutical composition
inflammatory
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057008518A
Other languages
English (en)
Korean (ko)
Other versions
KR20050074609A (ko
Inventor
케니스 지 카손
제랄딘 씨. 비. 해리맨
쇼미어 고시
Original Assignee
밀레니엄 파머슈티컬스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 밀레니엄 파머슈티컬스 인코퍼레이티드 filed Critical 밀레니엄 파머슈티컬스 인코퍼레이티드
Publication of KR20050074609A publication Critical patent/KR20050074609A/ko
Application granted granted Critical
Publication of KR101109348B1 publication Critical patent/KR101109348B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057008518A 2002-11-13 2003-11-12 Ｉ.ａ. 탈수초성 염증 질환을 치료하기 위한 ｃｃｒ１ 길항제 Expired - Fee Related KR101109348B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42594702P 2002-11-13 2002-11-13
US60/425,947 2002-11-13
PCT/US2003/035817 WO2004043965A1 (en) 2002-11-13 2003-11-12 Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease

Publications (2)

Publication Number Publication Date
KR20050074609A KR20050074609A (ko) 2005-07-18
KR101109348B1 true KR101109348B1 (ko) 2012-01-31

Family

ID=32313083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057008518A Expired - Fee Related KR101109348B1 (ko) 2002-11-13 2003-11-12 Ｉ.ａ. 탈수초성 염증 질환을 치료하기 위한 ｃｃｒ１ 길항제

Country Status (24)

Country Link
US (7) US20040106639A1 (enExample)
EP (2) EP1562954B1 (enExample)
JP (1) JP4644491B2 (enExample)
KR (1) KR101109348B1 (enExample)
CN (1) CN100343257C (enExample)
AR (1) AR041942A1 (enExample)
AT (2) ATE325124T1 (enExample)
AU (2) AU2003291452A1 (enExample)
BR (1) BR0316261A (enExample)
CA (1) CA2505874C (enExample)
CY (1) CY1107985T1 (enExample)
DE (2) DE60332663D1 (enExample)
DK (1) DK1562954T3 (enExample)
EA (1) EA007748B1 (enExample)
ES (2) ES2261979T3 (enExample)
IL (2) IL168384A (enExample)
MX (1) MXPA05005105A (enExample)
NO (1) NO331855B1 (enExample)
PL (1) PL211022B1 (enExample)
PT (1) PT1562954E (enExample)
SI (1) SI1562954T1 (enExample)
TW (1) TWI291467B (enExample)
WO (1) WO2004043965A1 (enExample)
ZA (2) ZA200504144B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
JP5308030B2 (ja) * 2004-12-17 2013-10-09 ミレニアム ファーマシューティカルズ， インコーポレイテッド ケモカインレセプターアンタゴニストの固体形態およびその使用方法
ZA200704921B (en) 2004-12-21 2008-09-25 Serono Lab Sulfonyl amino cyclic derivatives and use thereof
CA2592154C (en) 2005-01-31 2014-03-18 Laboratoires Serono S.A. N-hydroxyamide derivatives and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
ZA200801923B (en) 2005-09-01 2009-09-30 Ares Trading Sa Treatment of optic neuritis
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
CN101489556A (zh) * 2006-07-14 2009-07-22 伊莱利利公司 糖皮质激素受体调节剂及使用方法
WO2009015164A2 (en) * 2007-07-24 2009-01-29 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8288371B2 (en) * 2007-10-05 2012-10-16 Pharmacopeia, Llc Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation
EP2231675A1 (en) * 2007-11-30 2010-09-29 Millennium Pharmaceuticals, Inc. Process for the preparation of 5-cyclopropyl-5, 11-dihydro (1) benzoxepino (3, 4-b) -pyridin-5-ol using tmeda
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
WO2009089312A1 (en) 2008-01-11 2009-07-16 Eli Lilly And Company (e)-n-{3- [1-(8-fluoro-11h-10-oxa-1-aza-dibenzo [a,d] cycl0hepten-5ylidene)-propyl]-phenyl }-methynsulfon amide as glucocorticoid receptor modulator for the treatment of rheumatoid
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119973A1 (en) 1998-01-21 2002-08-29 Jay R. Luly Chemokine receptor antagonists and methods of use therefor

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US377729A (en) * 1888-02-07 Half to phillips
DE80449C (enExample)
DD80449A (enExample)
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
NL279409A (enExample) 1961-06-08
CH416624A (de) 1962-10-23 1966-07-15 Sandoz Ag Verfahren zur Herstellung von neuen heterocyclischen Verbindungen
NL132137C (enExample) * 1963-04-24
FR88751E (enExample) 1963-07-09 1967-06-07
GB1085406A (en) 1963-10-14 1967-10-04 Pfizer & Co C Aminoalkylphosphorus compounds, preparation thereof and reaction products with ketones
BE664609A (enExample) 1964-06-01
CH421138A (de) 1965-11-04 1966-09-30 Wander Ag Dr A Verfahren zur Herstellung von Thioxanthenderivaten
US3409621A (en) * 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
GB1206216A (en) 1967-07-18 1970-09-23 Pfizer & Co C Aminopropylidene dibenzoxepine tranquilizers
NL6905642A (enExample) 1968-04-12 1969-10-14
JPS4830064B1 (enExample) 1968-12-23 1973-09-17
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
DE2163657A1 (de) 1970-12-22 1972-07-13 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) N-substituierte Piperidinverbindungen
GB1323659A (en) 1971-04-10 1973-07-18 Yoshitomi Pharmaceutical Piperazine derivatives methods for their production and pharmaceuticl compositions containing them
CA1010870A (en) * 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) * 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) * 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (de) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel
US4547496A (en) * 1983-06-24 1985-10-15 Kyowa Hakko Kogyo Co., Ltd. Antiulcer [1] benzepino[3,4-b]pyridine and compositions
ES524680A0 (es) 1983-08-02 1984-12-16 Espanola Farma Therapeut Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
DE3402060A1 (de) * 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CS236550B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Způsob přípravy esterů piperazinoalkanolů dibenzo(b,e)thiepinové řady a jejich solí s kyselinou maleinovou
CS236549B1 (cs) 1984-02-02 1985-05-15 Miroslav Protiva Piperazinoalkanoly dibenzo(b,e)thiepinové řady a jejich soli s kyselinou maleinovou
CS240698B1 (cs) 1984-10-12 1986-02-13 Miroslav Protiva Substituované ll-(piperidinoalkyl)-6,ll-dihydrodibenzo (b,e)thiepin-ll-karbonitrily
JPH0665664B2 (ja) 1985-01-18 1994-08-24 大塚製薬株式会社 モルフアントリジン誘導体
SE8500273D0 (sv) * 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
WO1988000049A1 (fr) 1986-06-26 1988-01-14 Kyowa Hakko Kogyo Co., Ltd. Agent antiarythmique
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
ATE108453T1 (de) 1988-04-28 1994-07-15 Schering Corp Benzopyridopiperidin, -piperidyliden und - piperazin-verbindungen, zusammensetzungen, methoden zur herstellung und verwendung.
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
DE3838912A1 (de) * 1988-11-17 1990-05-23 Thomae Gmbh Dr K Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
JPH0694464B2 (ja) * 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
US5239083A (en) * 1991-03-11 1993-08-24 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives which inhibit steroid 5α reductase
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1992020681A1 (en) 1991-05-23 1992-11-26 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
CA2114009A1 (en) 1991-07-23 1993-02-04 Jesse K. Wong Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) * 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
WO1994011504A1 (en) 1992-11-10 1994-05-26 Genentech, Inc. C-c ckr-1, c-c chemokine receptor
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
UA54385C2 (uk) 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1996031470A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
EP0974583B1 (en) * 1995-09-13 2002-05-29 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivatives
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
DE29602088U1 (de) 1996-02-07 1996-04-04 Bümach Engineering International B.V., Emmen Verschraubbarer druckmittelbetätigter Arbeitszylinder mit Verschlußteilen zur Kopplung des Zylinderrohres
JP4176148B2 (ja) 1996-05-20 2008-11-05 帝人ファーマ株式会社 ジアリールアルキル環状ジアミン誘導体およびその治療薬としての使用
AU729415B2 (en) * 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998004554A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
TR199900561T2 (xx) 1996-09-13 1999-06-21 Schering Corporation G-protein i�levinin engellenmesi i�in ve �o�almaya y�nelik hastal�klar�n iyile�tirilmesi i�in yararl� trisiklik bile�ikler.
KR20000036102A (ko) 1996-09-13 2000-06-26 둘락 노먼 씨. 파르네실-단백질 트랜스퍼라제 억제제로서 유용한 치환된 벤조사이클로헵타피리딘
CN1122031C (zh) 1996-09-13 2003-09-24 先灵公司 用作法呢基蛋白转移酶抑制剂的取代的苯并芳庚并吡啶衍生物
CA2265764A1 (en) 1996-09-13 1998-03-19 Schering Corporation Tricyclic compounds useful as fpt inhibitors
EP0929544B1 (en) 1996-09-13 2004-11-10 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
HUP0000191A2 (hu) 1996-09-13 2001-04-28 Schering Corp. Farnezil-protein-transzferáz inhibitorként alkalmazható új triciklusos piperidinil-vegyületek
ES2235252T3 (es) 1996-09-13 2005-07-01 Schering Corporation Inhibidores triciclicos de la farnesil proteina transferasa.
CA2267500A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
ZA978792B (en) 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
WO1998015548A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU5803398A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU6517398A (en) 1997-03-27 1998-10-22 Kyowa Hakko Kogyo Co. Ltd. Therapeutic agent for autoimmune diseases
BR9808552A (pt) 1997-04-15 2000-05-23 Kyowa Hakko Kogyo Kk Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) * 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
JP2002515914A (ja) 1997-06-25 2002-05-28 ノボ ノルディスク アクティーゼルスカブ 新規へテロ環式化合物
US6048856A (en) * 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
HUP0101320A3 (en) * 1998-01-21 2002-11-28 Kyowa Hakko Kogyo Kk Benzo- and pyridobenzoxepine and -benzazepine derivatives and use thereof
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
AU2331199A (en) 1998-09-04 2000-03-27 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
MXPA04004826A (es) 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Antagonista del receptor de quimioquinas y metodos para su uso.
AU1549500A (en) 1998-12-02 2000-06-19 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
WO2001009094A2 (en) 1999-07-28 2001-02-08 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU6503900A (en) * 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
CN100524575C (zh) 2005-04-20 2009-08-05 三菱电机株式会社 过电流继电器
JP4715952B2 (ja) 2009-02-18 2011-07-06 村田機械株式会社 フロッグレッグ型移載装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119973A1 (en) 1998-01-21 2002-08-29 Jay R. Luly Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
EP1562954A1 (en) 2005-08-17
ATE468340T1 (de) 2010-06-15
CA2505874C (en) 2012-07-17
TW200413347A (en) 2004-08-01
AU2003291452A1 (en) 2004-06-03
US20050288319A1 (en) 2005-12-29
US20100249174A1 (en) 2010-09-30
DK1562954T3 (da) 2006-08-28
AU2008202965A1 (en) 2008-07-31
CA2505874A1 (en) 2004-05-27
ZA200504144B (en) 2007-04-25
TWI291467B (en) 2007-12-21
US7977350B2 (en) 2011-07-12
EP1669356B1 (en) 2010-05-19
ES2261979T3 (es) 2006-11-16
US20040106639A1 (en) 2004-06-03
IL210046A0 (en) 2011-07-31
HK1086011A1 (en) 2006-09-08
DE60305063T2 (de) 2006-11-16
AU2008202965B2 (en) 2012-03-22
DE60332663D1 (de) 2010-07-01
HK1074046A1 (en) 2005-10-28
EP1669356A1 (en) 2006-06-14
ATE325124T1 (de) 2006-06-15
JP2006508966A (ja) 2006-03-16
ZA200607868B (en) 2008-01-08
IL210046A (en) 2015-07-30
KR20050074609A (ko) 2005-07-18
MXPA05005105A (es) 2005-07-01
WO2004043965A1 (en) 2004-05-27
CN1738824A (zh) 2006-02-22
US20110230516A1 (en) 2011-09-22
PL377715A1 (pl) 2006-02-06
PT1562954E (pt) 2006-07-31
SI1562954T1 (sl) 2006-10-31
US20080139602A1 (en) 2008-06-12
EP1562954B1 (en) 2006-05-03
US9334283B2 (en) 2016-05-10
US8394817B2 (en) 2013-03-12
ES2346337T3 (es) 2010-10-14
CY1107985T1 (el) 2013-09-04
US20150005338A1 (en) 2015-01-01
IL168384A (en) 2011-01-31
AR041942A1 (es) 2005-06-01
NO331855B1 (no) 2012-04-23
NO20052272L (no) 2005-06-06
JP4644491B2 (ja) 2011-03-02
US20130289063A1 (en) 2013-10-31
EA200500803A1 (ru) 2005-10-27
DE60305063D1 (de) 2006-06-08
PL211022B1 (pl) 2012-03-30
BR0316261A (pt) 2005-10-11
EA007748B1 (ru) 2006-12-29
US7732459B2 (en) 2010-06-08
CN100343257C (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
US9334283B2 (en) CCR1 antagonists and methods of use thereof
KR20210019529A (ko) Glp-1 수용체 작용제 및 이의 용도
PL172054B1 (pl) Sposób wytwarzania nowych pochodnych fluoroalkoksybenzyloaminowych zwiazków heterocyklicznych zawierajacych azot PL PL PL PL PL PL
EP2286811B1 (en) Chemokine receptor antagonists and methods of use thereof
EP1204664A1 (en) Chemokine receptor antagonists and methods of use therefor
HK1074046B (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
HK1086011B (en) Ccr1 antagonists for the treatment of i.a demyelinating inflammatory disease
AU2012203599A1 (en) CCR1 antagonists for the treatment of I.A. demyelinating inflammatory disease
HK1154504B (en) Chemokine receptor antagonists and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150106

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20160118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20160118

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000